A gene therapy study developed by Dr Amit Nathwani (UCL Cancer Institute) and colleagues in collaboration with St. Jude Children's Research Hospital, Memphis, Tennessee, has shown that adults with haemophilia B benefit from the treatment, reducing need for injections with clotting factor to prevent bleeds. The findings of the six-person study mark the first evidence that gene therapy can reduce disabling, painful bleeding episodes in patients with the inherited blood disorder.
News and activities of the International Institute of Medicine and Science Asean Chapter of IIMS, Inc. California, USA - Health care, Life Science, Education, Research, Philanthropy. Asean is the economic organization of ten countries located in South East Asia: Brunei Darussalam, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam.
Monday, April 16, 2012
UK - Haemophilia gene therapy breakthrough (UCL)
A gene therapy study developed by Dr Amit Nathwani (UCL Cancer Institute) and colleagues in collaboration with St. Jude Children's Research Hospital, Memphis, Tennessee, has shown that adults with haemophilia B benefit from the treatment, reducing need for injections with clotting factor to prevent bleeds. The findings of the six-person study mark the first evidence that gene therapy can reduce disabling, painful bleeding episodes in patients with the inherited blood disorder.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment